Literature DB >> 31040211

Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations.

Jannick Prentoe1,2, Rodrigo Velázquez-Moctezuma3,2, Elias H Augestad3,2, Andrea Galli3,2, Richard Wang4, Mansun Law5, Harvey Alter6, Jens Bukh1,2.   

Abstract

About two million new cases of hepatitis C virus (HCV) infections annually underscore the urgent need for a vaccine. However, this effort has proven challenging because HCV evades neutralizing antibodies (NAbs) through molecular features of viral envelope glycoprotein E2, including hypervariable region 1 (HVR1) and N-linked glycans. Here, we observe large variation in the effects of removing individual E2 glycans across HCV strains H77(genotype 1a), J6(2a), and S52(3a) in Huh7.5 cell infections. Also, glycan-mediated effects on neutralization sensitivity were completely HVR1-dependent, and neutralization data were consistent with indirect protection of epitopes, as opposed to direct steric shielding. Indeed, the effect of removing each glycan was similar both in type (protective or sensitizing) and relative strength across four nonoverlapping neutralization epitopes. Temperature-dependent neutralization (e.g., virus breathing) assays indicated that both HVR1 and protective glycans stabilized a closed, difficult to neutralize, envelope conformation. This stabilizing effect was hierarchical as removal of HVR1 fully destabilized closed conformations, irrespective of glycan status, consistent with increased instability at acidic pH and high temperatures. Finally, we observed a strong correlation between neutralization sensitivity and scavenger receptor BI dependency during viral entry. In conclusion, our study indicates that HVR1 and glycans regulate HCV neutralization by shifting the equilibrium between open and closed envelope conformations. This regulation appears tightly linked with scavenger receptor BI dependency, suggesting a role of this receptor in transitions from closed to open conformations during entry. This importance of structural dynamics of HCV envelope glycoproteins has critical implications for vaccine development and suggests that similar phenomena could contribute to immune evasion of other viruses.

Entities:  

Keywords:  N-linked glycans; envelope breathing; envelope protein 2; hepatitis C virus; neutralizing antibodies

Year:  2019        PMID: 31040211      PMCID: PMC6525505          DOI: 10.1073/pnas.1822002116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

Review 1.  Structural dynamics, an intrinsic property of viral capsids.

Authors:  J Witz; F Brown
Journal:  Arch Virol       Date:  2001-12       Impact factor: 2.574

Review 2.  Virus particle dynamics.

Authors:  John E Johnson
Journal:  Adv Protein Chem       Date:  2003

3.  Molecular crowding inhibits intramolecular breathing motions in proteins.

Authors:  Lee Makowski; Diane J Rodi; Suneeta Mandava; David D L Minh; David B Gore; Robert F Fischetti
Journal:  J Mol Biol       Date:  2007-08-17       Impact factor: 5.469

Review 4.  Flying under the radar: the immunobiology of hepatitis C.

Authors:  Lynn B Dustin; Charles M Rice
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

5.  Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins.

Authors:  Anne Goffard; Nathalie Callens; Birke Bartosch; Czeslaw Wychowski; François-Loïc Cosset; Claire Montpellier; Jean Dubuisson
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 6.  Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome.

Authors:  H J Alter; L B Seeff
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

7.  Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses.

Authors:  Judith M Gottwein; Troels K H Scheel; Anne M Hoegh; Jacob B Lademann; Jesper Eugen-Olsen; Gorm Lisby; Jens Bukh
Journal:  Gastroenterology       Date:  2007-08-03       Impact factor: 22.682

8.  Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization.

Authors:  Emilia Falkowska; Francis Kajumo; Edie Garcia; John Reinus; Tatjana Dragic
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

9.  Complete replication of hepatitis C virus in cell culture.

Authors:  Brett D Lindenbach; Matthew J Evans; Andrew J Syder; Benno Wölk; Timothy L Tellinghuisen; Christopher C Liu; Toshiaki Maruyama; Richard O Hynes; Dennis R Burton; Jane A McKeating; Charles M Rice
Journal:  Science       Date:  2005-06-09       Impact factor: 47.728

10.  The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein.

Authors:  François Helle; Anne Goffard; Virginie Morel; Gilles Duverlie; Jane McKeating; Zhen-Yong Keck; Steven Foung; François Penin; Jean Dubuisson; Cécile Voisset
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

View more
  21 in total

1.  A Novel Approach To Display Structural Proteins of Hepatitis C Virus Quasispecies in Patients Reveals a Key Role of E2 HVR1 in Viral Evolution.

Authors:  Yimin Tong; Qingchao Li; Rui Li; Yongfen Xu; Yu Pan; Junqi Niu; Jin Zhong
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

2.  Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance.

Authors:  Valerie J Kinchen; Guido Massaccesi; Andrew I Flyak; Madeleine C Mankowski; Michelle D Colbert; William O Osburn; Stuart C Ray; Andrea L Cox; James E Crowe; Justin R Bailey
Journal:  J Clin Invest       Date:  2019-08-13       Impact factor: 14.808

3.  Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development.

Authors:  Fang Chen; Kenna Nagy; Deborah Chavez; Shelby Willis; Ryan McBride; Erick Giang; Andrew Honda; Jens Bukh; Phillip Ordoukhanian; Jiang Zhu; Sharon Frey; Robert Lanford; Mansun Law
Journal:  Gastroenterology       Date:  2019-12-04       Impact factor: 22.682

4.  Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response.

Authors:  Vijayamahantesh Vijayamahantesh; Tapas Patra; Keith Meyer; Mohamad-Gabriel Alameh; Erin K Reagan; Drew Weissman; Ranjit Ray
Journal:  J Virol       Date:  2022-05-25       Impact factor: 6.549

Review 5.  From Structural Studies to HCV Vaccine Design.

Authors:  Itai Yechezkel; Mansun Law; Netanel Tzarum
Journal:  Viruses       Date:  2021-05-04       Impact factor: 5.818

Review 6.  Structure-Based and Rational Design of a Hepatitis C Virus Vaccine.

Authors:  Johnathan D Guest; Brian G Pierce
Journal:  Viruses       Date:  2021-05-05       Impact factor: 5.818

Review 7.  Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies.

Authors:  Emmanuelle V LeBlanc; Youjin Kim; Chantelle J Capicciotti; Che C Colpitts
Journal:  Pathogens       Date:  2021-06-01

Review 8.  Mechanisms of HCV resistance to broadly neutralizing antibodies.

Authors:  Nicole Frumento; Andrew I Flyak; Justin R Bailey
Journal:  Curr Opin Virol       Date:  2021-07-28       Impact factor: 7.121

9.  An alternate conformation of HCV E2 neutralizing face as an additional vaccine target.

Authors:  Netanel Tzarum; Erick Giang; Rameshwar U Kadam; Fang Chen; Kenna Nagy; Elias H Augestad; Rodrigo Velázquez-Moctezuma; Zhen-Yong Keck; Yuanzi Hua; Robyn L Stanfield; Marlene Dreux; Jannick Prentoe; Steven K H Foung; Jens Bukh; Ian A Wilson; Mansun Law
Journal:  Sci Adv       Date:  2020-07-24       Impact factor: 14.136

10.  Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.

Authors:  Brian G Pierce; Zhen-Yong Keck; Ruixue Wang; Patrick Lau; Kyle Garagusi; Khadija Elkholy; Eric A Toth; Richard A Urbanowicz; Johnathan D Guest; Pragati Agnihotri; Melissa C Kerzic; Alexander Marin; Alexander K Andrianov; Jonathan K Ball; Roy A Mariuzza; Thomas R Fuerst; Steven K H Foung
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.